하시모토 갑상선염과 동반된 갑상선 유두암에서 BRAFV600E의 발현과 임상적 특징 = Clinical Characteristics and Expression of BRAFV600E in the Papillary Thyroid Carcinoma Coexisting Hashimoto's Thyroiditis

다국어 초록 (Multilingual Abstract)

Background: An association between Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) is still controversial. Studies to date established the coexistence of HT in 11% to 36% of PTC patients. BRAFV600E mutation was presented 90% with no HT, 64% with HT in PTC patients. Therefore, BRAFV600E mutation is associated with the pathogenesis of PTC arising in HT. The purpose of this study was to identify predictive factors for the coexistence of PTC and HT and to evaluate the association of the BRAFV600E mutation with the clinicopathological features of coexistence of PTC and HT.
Methods: A total of 247 patients underwent surgery for thyroid disorders between January 2007 and April 2009. In all, 212 patients was diagnosed as thyroid papillary carcinoma only (PTC group), 33 had coexistence of PTC and HT (PTC+HT group), and 2 had been diagnosed with HT. DNA was extracted from paraffin embedded thyroid tumor specimens taken from 99 patients with PTC, 13 coexistence of PTC and HT, and 2 was HT. The presence of the BRAFV600E mutation was determined by polymerase chain reaction amplification of exon 15 followed by direct sequencing.
Results: Among clinicopathological features sex, age, tumor size and capsule invasion was not significant between PTC group and PTC+HT group. Lymph node metastasis and stage was significantly lower in PTC+HT group than PTC group (p=0.044). BRAFV600E mutation was found in 34 of the 99 PTC group (34.3%), 1 of the 13 PTC+HT group and 2 HT show no BRAFV600E mutation.
Conclusion: These data demonstrated that the coexistence of PTC and HT was less aggressive than PTC only.

목차 (Table of Contents)

• 서론
• 대상 및 방법
• 1. 대상
• 2. 방법
• 3. 통계처리
• 결과
• 1. 갑상선 유두암 환자의 임상적 특징
• 2. BRAFV600E 변이와 빈도
• 3. 갑상선 유두암에서 하시모토 갑상선염 동반 유무와 예후 인자와의 관계
• 고찰
• 결론
• 참고문헌

참고문헌 (Reference)

1 Cheema Y, "What is the biology and optimal treatment for papillary microcarcinoma of the thyroid?" 134 (134): 160-162, 2006

2 Kurukahvecioglu O, "Total thyroidectomy for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma" 24 (24): 510-516, 2007

3 Eisenberg BL, "Thyroid cancer with coexistent Hashimoto's thyroiditis. Clinical assessment and management" 124 (124): 1045-1047, 1989

4 Hilger RA, "The Ras Raf-MEK-ERK pathway in the treatment of cancer" 25 : 511-518, 2002

5 Dailey ME, "Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland" 70 (70): 291-297, 1955

6 Kim KH, "Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis" 55 (55): 540-545, 2005

7 Davies H, "Mutations of the BRAF gene in human cancer" 417 : 949-954, 2002

8 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population" 연세대학교의과대학 45 (45): 818-821, 2004

9 Cheema Y, "Is tumor size the best predictor of outcome for papillary thyroid cancer?" 13 (13): 1524-1528, 2006

10 Loh KC, "Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma" 84 (84): 458-463, 1999

11 Boi F, "High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies" 153 (153): 637-642, 2005

12 Cipolla C, "Hashimoto thyroiditis coexistent with papillary thyroid carcinoma" 71 (71): 874-878, 2005

13 Wirtschafter A, "Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis" 107 (107): 95-100, 1997

14 Unger P, "Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link?" 34 (34): 764-769, 2003

15 Hamacher C, "Expression of functional stimulatory guanine nucleotide binding protein in nonfunctioning thyroid adenomas is not correlated to adenylate cyclase activity and growth of these tumors" 80 (80): 1724-1732, 1995

16 Donohue JH, "Do the prognosis of papillary and follicular thyroid cancer differ?" 148 : 168-173, 1984

17 Ruegemer JJ, "Distant metastases in differentiated thyroid carcinoma : a multivariate analysis of prognostic variables" 67 : 501-508, 1988

18 Kebebew E, "Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited" 25 (25): 632-637, 2001

19 Singh B, "Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome" 126 (126): 1070-1076, 1999

20 Singh B, "Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma : impact on presentation, management, and outcome" 126 (126): 1070-1076, 1999

21 Namba H, "Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers" 88 : 4393-4397, 2003

22 Kashima K, "Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma" 8 (8): 197-202, 1998

23 Puxeddu E, "BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas" 89 : 2414-2420, 2004

24 Nikiforova MN, "BRAF mutation in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas" 88 : 5399-5404, 2003

25 Okayasu I, "Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans" 76 (76): 2312-2318, 1995

26 Fusco A, "A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases" 328 : 170-172, 1987